Side-by-side · Research reference

GHRP-6vsMT-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED10/36 cited

BFDA-ApprovedHUMAN-REVIEWED9/51 cited

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

MT-1

α-MSH Analogue · FDA-Approved

16 mgImplant dose

13 AAPeptide lengthChawathe 2026

2019FDA approval

SQ Implant · 60-Day Release

01Mechanism of Action

Parameter

GHRP-6

MT-1

Primary target

Ghrelin receptor (GHS-R1a)Bowers 1990

Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis

Downstream effect

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010

Feedback intact?

—

Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production

Origin

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026

Antibody development

—

02Dosage Protocols

Parameter

GHRP-6

MT-1

Standard dose

100–200 mcg per injectionBowers 1990

16 mg subcutaneous implant

FDA-approved formulation (Scenesse).

Frequency

1–3× per day

Every 60 days

Sustained release implant — no daily administration required.

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 1 + clinical practiceBowers 1990

Phase 3 RCT / FDA-approved orphan drug

Duration

8–12 weeks on / 4 off

Seasonal use (spring–autumn typical)

Aligned with peak UV exposure months.

Reconstitution

Bacteriostatic water

—

Timing

Pre-meal preferred for appetite support

—

Half-life

~15 minMalagón 1999

—

Indication

—

Erythropoietic protoporphyria (EPP)

Narrow FDA approval — not licensed for cosmetic tanning.

Route

—

Subcutaneous implant — upper arm or abdomen

Stability

—

Norleucine/D-Phe substitutions enhance peptidase resistance

Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).

04Side Effects & Safety

Parameter

GHRP-6

MT-1

Hunger

Pronounced — defining feature vs ipamorelin

—

Cortisol elevation

Mild

—

Prolactin elevation

Mild

—

Injection site reaction

Mild

—

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

Nausea

—

Common (>10%) — mild, transient

Implant site reaction

—

Erythema, bruising, tenderness at insertion site

Hyperpigmentation

—

Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010 Habbema 2017

Expected melanogenic response — complicates pigmented lesion surveillance.

Melanocytic changes

—

Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017

Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.

Headache

—

Occasional (MC1R-independent melanocortin effects)

Photosensitivity (paradoxical)

—

Rare phototoxic reactions despite melanin increase

Contamination risk (unregulated)

—

Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010 Habbema 2017

Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.

Absolute Contraindications

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

MT-1

·Hypersensitivity to afamelanotide or excipients
·Hepatic impairment (no safety data)
·Renal impairment (no safety data)

Relative Contraindications

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

MT-1

·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
·Pregnancy/lactation (insufficient data)
·Photosensitive dermatoses (other than EPP)

05Administration Protocol

Parameter

GHRP-6

MT-1

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.

2. Injection site

SQ — abdomen. Rotate sites.

Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.

3. Timing

Pre-meal for appetite support; pre-sleep for GH alignment.

Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.

5. Needle

29–31G, 4–8 mm insulin syringe.

Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.